ACTRN12619000953134
Recruiting
Phase 4
A double-blind study to evaluate the effectiveness of bioavailability enhancers to increase blood absorption of antioxidants and fat-soluble nutrients over a 48-hour period in otherwise healthy individuals.
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- RDC Global Pty Ltd
- Enrollment
- 610
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Men and women aged over 18 years with normal dietary habits (no medically prescribed diet or slimming diet) including good representation of age and gender specifics.
- •\- Clinically healthy, BMI 18\.5\-39\.9
- •\- No history or evidence of clinically significant medical conditions including, but not limited to, cardiovascular, neurological, psychiatric, renal, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or haematological abnormalities that are uncontrolled.
- •\- Participant’s full agreement and ability to consent to participation in the study
- •\- Participant’s ability to participate fully and comply with demands of the study including attendance at all scheduled blood collection time points.
- •\- Female participants must be on a form of prescribed birth control (e.g. oral contraceptive pill)
Exclusion Criteria
- •\- Allergy to the investigational material
- •\- Previous history of hematologic diseases (e.g. known susceptibility to thrombosis)
- •\- Concomitant use of anticoagulant drugs (e.g. Warfarin Sodium) and any other prescribed medication (not for control of previously mentioned conditions above) expect for females on the oral contraceptive pill
- •\- Female participants currently pregnant, lactating or undergoing fertility treatment
- •\- Regular use of supplements containing the investigational material (e.g. omega\-3 fatty acids), in the last 3 months, regular consumption of foods containing the investigational material (e.g. fish for omega\-3, red meat and eggs for CoQ10\)
- •\- High alcohol consumption (equal to 21 standard drinks/week)
- •\- Reported participation in another trial 1 month before the start of the study
- •\- Recent history (within 12 months) of substance abuse including alcohol
- •\- Development of serious, adverse events/reactions including but not limited to; fainting, life\-threating dehydration and/or serious bruising from blood sampling, excessive and prolonged diarrhoea or gastrointestinal upset from fish oil consumption.
- •\- Received treatment (radio \&/or chemotherapy) for cancer (excluding BCC skin cancer) in past 2 years.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
The Effect of Botox Applied in TC-3 Gel in Patients Suffering From Overactive Bladder.Overactive bladder (OAB) syndrome (in women), as defined by the International Continence Society (ICS): severe urgency with or without urge urinary incontinence, usually accompanied with increased daytime frequency and nocturia, in the absence of urinary tract infection or other obvious patology.MedDRA version: 14.1Level: LLTClassification code 10059617Term: Overactive bladderSystem Organ Class: 100000004857Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]EUCTR2012-005344-15-CZAdyton, s.r.o.
Not yet recruiting
Phase 2
Homoeopathic Treatment of Piles.CTRI/2024/06/068239The Calcutta Homoeopathic Medical College and Hospital
Active, not recruiting
Not Applicable
A randomised, double-blind study to assess the efficacy and safety of prophylactis use of maribavir versus oral ganciclovir for the prevention of cytomegalovirus disease in recipients of orthotopic liver transplants - NDPatient undergone to orthotopic liver transplantsMedDRA version: 9.1Level: LLTClassification code 10011831Term: Cytomegalovirus infectionEUCTR2007-004729-16-ITVIROPHARMA INCORPORATED348
Active, not recruiting
Not Applicable
Double blind, placebo-controlled study of efficacy, safety and tolerance of raloxifene as an adjuvant treatment for negative symptoms of schizophrenia in postmenopausal women”Estudio doble ciego controlado con placebo de la eficacia, seguridad y tolerancia del raloxifeno como tratamiento coadyuvante de los síntomas negativos de la esquizofrenia en mujeres postmenopáusicas.Trastorno esquizofrénicoEUCTR2004-004281-32-ESSan Joan de Déu. Serveis de Salut Mental
Active, not recruiting
Not Applicable
Examination of effictiveness of iron containing infusion in preventing anemia after heart surgery in childreEUCTR2014-002107-16-ATGeneral Hospital Linz